Recent Market Performance and Price Trends
On 9 January 2026, TruAlt Bioenergy’s shares closed with a decline of 1.10%, underperforming the Sensex which fell by 0.53% on the same day. The stock has been on a downward trajectory for two consecutive sessions, accumulating a loss of 4.2% over this period. This underperformance extends beyond the immediate term, with the stock falling 6.09% over the past week compared to the Sensex’s 2.36% decline.
Over the last month, the stock declined by 4.90%, significantly lagging the Sensex’s modest 1.10% fall. The three-month performance is particularly stark, with TruAlt Bioenergy plunging 23.52% while the Sensex posted a positive return of 1.90%. Year-to-date, the stock has lost 4.64%, again underperforming the broader market’s 1.74% decline.
Longer-term figures reveal a flat return over one, three, five, and ten-year periods, with the stock generating 0.00% returns in each timeframe. This contrasts sharply with the Sensex’s robust gains of 7.88% over one year, 37.84% over three years, 71.65% over five years, and an impressive 235.82% over ten years.
Technically, TruAlt Bioenergy is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
See What's Driving the Rally →
Financial Metrics and Fundamental Assessment
TruAlt Bioenergy operates within the commodity chemicals sector and currently holds a Market Capitalisation Grade of 3. The company’s Mojo Score stands at 20.0, with a Mojo Grade of Strong Sell, a rating assigned on 17 December 2025. This represents a new classification as the stock was previously not rated.
Financially, the company has reported operating losses, which have contributed to a weak long-term fundamental strength. The average debt-to-equity ratio is recorded at 0 times, indicating a low leverage position. However, the company’s return on capital employed (ROCE) is negative, reflecting the impact of losses on capital efficiency.
Quarterly figures reveal operating profit to interest coverage at a low of -0.31 times, net sales at ₹104.48 crores, and a PBDIT (profit before depreciation, interest, and taxes) of -₹11.79 crores, all marking the lowest levels in recent periods. These figures underscore the financial pressures faced by the company.
Valuation and Profitability Insights
Despite the challenges, TruAlt Bioenergy’s ROCE is reported at 8.9, which is considered an attractive valuation metric. The enterprise value to capital employed ratio stands at 1.7, suggesting a valuation that may be reasonable relative to the company’s capital base.
Interestingly, while the stock has generated no returns over the past year, the company’s profits have risen by 342% during the same period. This divergence between profit growth and share price performance highlights a complex dynamic in the company’s valuation and market perception.
Holding TruAlt Bioenergy from Commodity Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Sector Context and Comparative Performance
Within the commodity chemicals sector, TruAlt Bioenergy’s recent underperformance is notable. The stock has consistently lagged behind sector benchmarks and the broader market indices, including the Sensex. The sector itself has experienced mixed performance, but TruAlt Bioenergy’s declines have been more pronounced.
The company’s share price trajectory, combined with its financial metrics, places it in a challenging position relative to peers. The sustained losses and negative returns on capital employed contrast with some sector participants who have managed to maintain profitability and positive returns.
Summary of Key Indicators
To summarise, TruAlt Bioenergy’s stock is trading near historic lows, with a closing price just 0.05% above its 52-week low. The stock has underperformed the Sensex across multiple time horizons, including daily, weekly, monthly, quarterly, and year-to-date periods. The company’s financial results reflect operating losses, negative ROCE, and low interest coverage ratios, despite a notable increase in profits over the past year.
These factors have contributed to the assignment of a Strong Sell Mojo Grade, reflecting the current market assessment of the company’s financial health and stock performance.
Conclusion
TruAlt Bioenergy’s recent stock performance and financial disclosures indicate a period of significant difficulty for the company within the commodity chemicals sector. The all-time low share price, combined with weak financial ratios and a negative return profile, highlight the severity of the current situation. The company’s valuation metrics and profit growth present a nuanced picture, but the prevailing market sentiment remains cautious.
Unlock special upgrade rates for a limited period. Start Saving Now →
